Globally, people lost confidence in the importance of routine childhood vaccines against lethal diseases like measles and polio, a survey finds; advocates say that the proposed price of about $50 a kit for naloxone could be too expensive; Bipartisan Senate legislation introduced this week would cap insulin at $35 per month for those with private insurance.
Faith Lost in Childhood Vaccines, Says UNICEF
A new report from UNICEF suggests that people around the world lost confidence in the necessity of routine childhood vaccines against deadly diseases like measles and polio during the COVID-19 pandemic, according to NBC News. Public perception of vaccines for children lowered between 2019 and 2021 in 52 of 55 surveys. The organization said that the data was a “worrying warning signal” of increasing vaccine hesitancy and misinformation, shrinking trust in governments, and political polarization. This was after the largest sustained backslide in childhood immunization in a generation occurred during pandemic disruptions.
Advocates Worry Naloxone Price Will Reduce Access
Naloxone (Narcan), the nasal spray that reverses opioid overdoses, will retail for “less than $50” per each 2 pack of 4-milligram sprays, said the manufacturer on Thursday, inciting criticism that the price would make it inaccessible for many during a drug crisis killing over 100,000 people per year, reported The Washington Post. Drug manufacturer Emergent BioSolutions made the announcement weeks after the FDA approved the drug without a prescription to make it easy to buy and plentiful. However, advocates worry that price might be a barrier.
Senate Legislation Would Cap Insulin at $35/Month for Those With Private Insurance
Bipartisan Senate legislation presented this week would cap the cost of insulin at $35 per month for those with private insurance, according to CNBC. The bill drafted by Senators Jeanne Shaheen, D-N.H., and Susan Collins, R-Maine, comes 2 months following President Joe Biden’s call on Congress during his SCOTUS address to broaden the insulin price cap to the millions of people with diabetes who have private insurance. The President’s Inflation Reduction Act capped the price of insulin at $35 for seniors on Medicare when it became law in 2022, but a push to include people with private insurance deteriorated in Congress last year due to Republican opposition.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More